|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on May 17, 2002; DOI 10.1182/blood-2002-01-0161.
GENE THERAPY
From Biologie et Thérapeutique des Pathologies
Immunitaires CNRS/UPMC UMR 7087, the Service d'Anatomie Pathologique,
and the Service de Radiothérapie, Hôpital
Pitié-Salpêtrière, Paris, France.
Clinical data indicate that after allogeneic hematopoietic stem
cell transplantation (HSCT) for hematological malignancies, the
graft-versus-leukemia (GVL) effect is in large part mediated by the
graft-versus-host reaction (GVHR), which also often leads to
graft-versus-host disease (GVHD). Controlling alloreactivity to
prevent GVHD while retaining GVL poses a true dilemma for the successful treatment of such malignancies. We reasoned that suicide gene therapy, which kills dividing cells expressing the thymidine kinase (TK) "suicide" gene using time-controlled administration of
ganciclovir (GCV), might solve this dilemma. We have previously shown
that after infusion of allogeneic TK T cells along with HSCT to an
irradiated recipient, an early and short GCV treatment efficiently
prevents GVHD by selectively eliminating alloreactive T cells while
sparing nonalloreactive T cells, which can then contribute to
immune reconstitution. Nevertheless, it remained to be established that
this therapeutic strategy retained the desired GVL effect.
Hypothesizing that a contained GVHR would be essential, we evaluated
the GVL effect using different protocols of GCV administration. We were
able to show that when the GCV treatment is initiated at, or
close to, the time of grafting, GVHD is controlled but GVL is lost. In
contrast, when the onset of GCV administration is delayed until day 6, a potent GVL effect is retained while GVHD is still controlled. These
data emphasize that, by a time-optimized scheduling of the
administration of GCV, this TK/GCV strategy can be tuned to efficiently
treat malignant hemopathies.
(Blood. 2002;100:2020-2025) Allogeneic hematopoietic stem cell transplantation
(HSCT) is the treatment of choice for many hematological malignancies. Following the intensive conditioning of the recipient before
transplantation aimed at eliminating malignant cells, donor T
cells present in the graft contribute to the graft-versus-leukemia
(GVL) effect1 by eliminating residual leukemic cells
expressing disparate major histocompatibility complex (MHC)
antigens and/or tumor-associated antigens. Donor T cells also improve
engraftment2 and provide a graft-versus-infection (GVI)
effect for patients who are severely immunodeficient owing to the
conditioning.3,4 Unfortunately, in addition to their
ability to provide such beneficial effects, donor T cells are also
responsible for the life-threatening graft-versus-host disease (GVHD)
that is initiated by mature T cells that recognize MHC alloantigens
presented by recipient cells.5,6 This complication can be
circumvented by the removal of mature T cells from the graft, but only
to the detriment of engraftment, as well as of the GVI and GVL effects.
Thus, the GVHD and GVL effects are closely linked, and controlling
alloreactivity to prevent GVHD while retaining the GVL effect
represents the challenge for successful HSCT.
We and others have developed a strategy for controlling GVHD that
relies on ex vivo transduction of donor T cells carrying a suicide gene
encoding Herpes simplex type 1 thymidine kinase (TK). The
expression of the TK transgene allows the metabolism of the nucleoside
analog ganciclovir (GCV) into triphosphated-GCV (the active form of
GCV), which blocks DNA elongation and thereby causes cell
death.7-9 When donor TK T cells divide after
recognizing recipient alloantigens, they become sensitive to, and can
be killed by, GCV administration.10,11 Suicide gene
therapy permits the selective elimination of those T cells that
recognize recipient alloantigens, while preserving the T cells that did
not divide during the treatment with GCV.12 In preclinical
experiments using TK T cells from transgenic mice, we and
others have previously demonstrated that this therapeutic approach (1)
efficiently prevents GVHD,13,14 (2) does not impair
engraftment after either myeloablative13,15,16 or
nonmyeloablative17 conditioning, and (3) spares a pool of nondividing donor TK T cells that further contributes to the
recipient immune system reconstitution.12
To date, all preclinical data using the TK/GCV system in the field of
allogeneic HSCT were obtained under conditions where a GVL effect was
not required. The clinical relevance of this therapeutic strategy for
the treatment of hematological malignancies thus remained to be
established by a demonstration that it permits the simultaneous
control of GVHD while retaining the desired GVL effect. In this work,
using a murine model of leukemia, we show that when the GCV treatment
is initiated at, or close to, the time of grafting, GVHD is indeed
controlled, but the GVL effect is lost. In contrast, when the onset of
GCV administration is delayed until day 6, a potent GVL effect is
retained while GVHD is still controlled.
Mice
Experimental GVHD and drug administration
Analysis of in vivo T-cell proliferation T cells from double-transgenic (hCD4 × TK) mice were stained with the 5- and 6- carboxyfluorescein diacetate succinimidyl ester (CFSE): 1 × 107 cells per milliliter were incubated for 10 minutes at 37°C, 5% CO2 in a medium (RPMI 1640) containing CFSE at a concentration of 1.5 µM. Staining was stopped by addition of fetal calf serum to reach a concentration of 20% of the final volume. Labeled cells were washed twice in phosphate buffer saline, numbered, and injected intravenously with BM cells in lethally irradiated mice. Splenocytes from grafted animals were collected at day 21/2, day 31/2, or day 61/2 after transplantation. Cell proliferation was studied by flow cytometry as the sequential loss of CFSE fluorescence upon cell division after gating on donor (hCD4+) CD4 and CD8 populations.Flow cytometrical analysis Spleens from grafted animals were digested with collagenase and DNAse, and splenocytes were incubated with 2.4.G2 anti-Fc receptor monoclonal antibody (mAb). Transplanted mature donor T cells and their progeny were identified by their expression of the hCD4 transgene. For analysis of chimerism, cells were stained with combinations of the following mAbs: phycoerythrin (PE)-labeled anti-CD3 (clone 145-2c11; Pharmingen, San Diego, CA); fluorescein isothiocyanate-labeled anti-B220 (clone RA3-6B2; Caltag Laboratories, San Francisco, CA); biotinylated anti-H-2Kd (clone SF1-1.1; Pharmingen) revealed with tricolor-labeled streptavidin (Caltag); and PE-labeled anti-H-2Kb (clone CTKb; Caltag). For CFSE experiments, splenocytes were stained with the following mAbs: allophycocyanin-labeled anti-hCD4 (clone S3.5; Caltag); PE-labeled anti-CD4 (clone RMH-5; Pharmingen); and tricolor-labeled anti-CD8 (clone CT-CD8a; Caltag). Events were acquired on a FACSCalibur (Becton Dickinson, San Jose, CA) and analyzed by means of CellQuest software (Becton Dickinson).Leukemia model P815 mastocytoma cells that are of DBA/2 mouse origin express H-2d MHC molecules. First, 2 × 103 P815 cells were injected intravenously in the retro-orbital sinus to recipients at the time of BMT. Clinical signs of leukemia were macroscopic tumor at the site of leukemic cell injection followed in most cases by lower-limb paralysis. Leukemic cells were also identified in peripheral blood by the surface expression of H-2d (recipient-type) but not H-2b (donor-type) histocompatibility antigens.Histopathological examination Liver samples were prepared in Bouin fixative and embedded in paraffin, and sections were stained with hematoxylin and eosin. A pathologist unaware of treatment evaluated slides. GVHD lesions were scored as described previously.21Statistical analysis Statview software (Abacus Concepts, Berkeley, CA) was used for statistical analysis. Kaplan-Meier survival curves were established for each group. Mice suffering from advanced-stage GVHD were killed for histopathological examination and considered dead in the Kaplan-Meier analysis. Survival differences between the 2 groups were determined by means of the log-rank test. Analysis of variance (ANOVA) was used to compare GVHD scores. P is indicated only when differences between the 2 groups were statistically significant.
Optimizing the GCV treatment protocol according to the kinetics of T-cell proliferation following allogeneic transfer We have previously shown that a 7-day GCV treatment initiated immediately after grafting provides a good prophylaxis against GVHD.13 On the basis of experimental as well as clinical data, we hypothesized that preserving the GVL effect would require letting the graft-versus-host reaction (GVHR) proceed for a limited period of time, and then stopping it before GVHD appears and becomes uncontrollable. Since the TK/GCV approach is based on the selective killing of dividing cells, we reasoned that a careful examination of T-cell division would help define the optimal GCV protocol for achieving this goal.Using CFSE-cell staining, we analyzed T-cell division kinetics
after allogeneic BMT, as well as after GCV administration. CFSE-stained
TK T cells were infused together with BM cells from wild-type
B6 mice into lethally irradiated semiallogeneic B6 × D2
F1 recipients. To unambiguously identify transplanted donor T cells, we used T cells obtained from double-transgenic mice expressing, in addition to the TK transgene, the hCD4 marker molecule on both CD4+ and CD8+ T
cells.15,19 Spleen cells from mice that received
transplants were collected at different time points after BMT, and
donor T-cell division was assessed by the sequential loss of CFSE
fluorescence intensity after gating on
hCD4+CD4+ and hCD4+CD8+
double-positive populations. Using a similar approach, we recently demonstrated that after injection of allogeneic donor T cells (without
BM cells) into lethally irradiated mice, alloreactive and
nonalloreactive T cells can be distinguished on the basis of their
division rate and phenotypic differences.22 In the current
experiments, we observed that CD4+ and CD8+
donor T cells present in the spleen of grafted animals had already started to divide by day 21/2, and that at day 31/2, the
vast majority of donor T cells had divided several times (Figure
1A). We thus reasoned that a short GCV
treatment administered from day 1 to day 3 after BMT should be
sufficient to eliminate most alloreactive T cells and, therefore, to
control GVHD. Additionally, shortening the duration of the GCV
treatment from 7 days (as initially described13) to 2 days
should affect fewer nonalloreactive T cells,12 including those that recognize tumor-associated antigens and might participate in
the nonallogeneic part of the GVL effect. When GCV treatment was
administered from day 1 to day 3 after BMT, we did not observe any cell
division in CD4+ and CD8+ donor T cells during
the period of GCV administration (Figure 1A). At day 31/2, we
observed an approximately 10-fold decrease of
hCD4+CD4+ and hCD4+CD8+
T-cell counts as compared with untreated animals, illustrating the
cytolytic effect of GCV on dividing TK T cells (Figure 1B). At day 61/2 (31/2 days after discontinuation of GCV),
numerous cell divisions had occurred in both CD4+ and
CD8+ donor T cells. Thus, these data suggest that a short
GCV administration should suffice to eliminate alloreactive T cells
while sparing at least a portion of the nonalloreactive donor TK
T cells.
Short and early GCV treatment protects against GVHD but also prevents the GVL effect We next evaluated the efficacy of GVHD control in allografted mice receiving a day 1-to-day 3 GCV treatment. This short treatment prevented GVHD as efficiently as the day 0-to-day 7 GCV treatment.13,15,16 At day 60, 85% of the treated mice were still alive (Figure 2A) with a histopathological score (Figure 2B) comparable to that observed with the 7-day GCV treatment. In contrast, all untreated mice died (Figure 2A) with characteristic clinical signs (weight loss, skin lesions, and hunching), and histological signs (lymphocyte infiltration and parenchymal injury of liver) of GVHD (Figure 2B). More than 95% of the splenocytes from GCV-treated animals were of donor H-2b and not of recipient H-2d origin in both the B- and T-cell compartments, attesting to a good engraftment (not shown). Thus, a 2-day GCV treatment started at day 1 after grafting is efficient in preventing GVHD.
We next investigated whether a GVL effect could be observed with the use of such GCV treatment. Leukemia was induced in lethally irradiated mice by injecting 2 × 103 P815 cells intravenously at day 0. This led to 100% mortality in mice grafted with TCD-BM (Figure 2A), with death being preceded by the appearance of leukemic cells in peripheral blood, a retro-orbital tumor at the site of injection, and, in most cases, a hind-limb paralysis. Similar mortality was observed in TCD-BM-grafted mice treated with GCV, indicating that GCV was not toxic for the leukemic cells (not shown). We then assessed whether the addition of TK T cells to the TCD-BM and the P815 cells, under our GCV treatment scheme, provided a GVL effect. In this experiment, all mice died with characteristic biological and clinical signs of leukemia, with the same kinetics as those observed for control mice not receiving the TK T cells (Figure 2A). The presence of leukemic cells in the peripheral blood of mice was
unequivocally confirmed by their expression of recipient-type H-2Kd, and not donor-type H-2Kb, MHC class I
molecules (Figure 3). Thus, when
alloreactive T cells are eliminated by GCV treatment early after BMT,
GVHD is controlled, but there is no GVL effect.
Delayed GCV treatment permits GVL effect without altering protection against GVHD We reasoned that if GCV administration was delayed, alloreactive donor T cells might be maintained for a longer time after BMT, thus allowing a time-limited GVHR that might favor the GVL effect. When mice received the same 2-day GCV treatment from day 31/2 or day 6 rather than from day 1, they all survived without any clinical signs of GVHD (Figure 4A). Compared with mice receiving a GCV treatment starting at day 0 or day 1, histological signs of GVHD were either absent when the treatment was delayed to day 31/2 or slightly increased when the treatment started at day 6 (Figure 4B). Splenocytes of GCV-treated animals were of donor H-2b, and not of recipient H-2, origin (greater than 97%), in the B- and T-cell compartments, attesting to satisfactory engraftment (not shown). This indicates that GCV administration can be delayed without losing therapeutic efficacy.
When GCV was administered at day 31/2 to mice challenged with
P815 leukemic cells, leukemia-associated mortality was significantly delayed compared with mice treated at day 1 (P < .05),
although 7 of 10 mice still died of leukemia (Figure 4A). The 3 surviving mice had neither clinical signs of leukemia nor clinical or
histopathological signs of GVHD (Figure 4B). When we further delayed
GCV administration to day 6, only 2 of 10 mice died of leukemia. The 8 mice that survived until day 60 (P < .001 compared with
mice treated by GCV at day 1) had no detectable leukemic cells in the
peripheral blood at the end of the experiments (Figure
5).
Taken together, these results indicate that by adjusting the modalities of GCV administration, one can obtain a potent GVL effect without compromising the protection against GVHD. We also tested whether donor T cells with antileukemeic activity persisted after GCV treatment administered at day 6. Mice protected from GVHD and leukemia by the GCV-controlled GVHR were rechallenged with P815 cells at day 15. Four of 4 such mice developed and eventually died of leukemia. Cyclosporin A impairs the GVL effect mediated by TK T cells after allogeneic BMT CsA administered alone or in combination with methotrexate is the standard preventive treatment of GVHD.23 This immunosuppressive agent may, however, interfere with the antileukemic effect of donor TK T cells by inhibiting T-cell proliferation.24,25 We thus evaluated whether the presence of CsA before and during GCV administration had an impact on the GVL effect. To answer this question, CsA was administered from day 2 before transplantation until day 10 after BMT to mice receiving a 2-day GCV administration schedule starting at day 6 after BMT. Under these experimental conditions, we have recently demonstrated that CsA does not alter the capacity of GCV to control GVHD.26 In the present experiment, the GVL effect was dramatically altered in mice challenged with P815 cells, when compared with mice not receiving CsA. Indeed, 60% of mice treated with GCV and CsA developed typical signs of leukemia and died between day 23 and day 26 (Figure 4A). These results indicate that combining a CsA prophylactic treatment with the TK/GCV approach might result in the loss of the GVL effect.
The GVL effect is one of the main benefits brought by donor T cells after allogeneic HSCT. The antileukemic activity of allogeneic donor T cells has been directly evidenced by remissions observed after donor lymphocyte infusions into patients experiencing relapse of hematological malignancies following allogeneic BMT.27-29 More recently, such a role for alloreactive T cells has also been shown in solid tumors after partial or complete regression of metastatic renal cell carcinoma was obtained in patients receiving allogeneic HSCT.30 These alloreactivity-based approaches have proven to be promising for the treatment of leukemia as well as solid tumors, although their usefulness remains limited by life-threatening GVHD. Here, we tested the efficacy of the TK/GCV strategy in preclinical conditions where a GVL effect is required. One of the main advantages of this TK/GCV strategy is its versatility and, in particular, the time-controlled delivery of the ablative signal, that is, GCV. Although few experimental data suggest that some GVL effect can be obtained independently of alloreactivity,31 it is clear from numerous studies that, in most cases, the GVHR is likely to be the main driving force behind the GVL effect.1 We thus anticipated that an optimal GVL effect would be achieved only by allowing a limited GVHR to proceed. However, we have previously shown that delaying GCV administration beyond a certain time point can result in the appearance of an uncontrollable GVHD.21 We thus assessed the consequences of delaying and reducing GCV administration on both the GVHD and the GVL effect. We first observed that a 2-day GCV treatment administered at day 1 after transplantation was as efficient in eliminating alloreactive donor T cells and controling GVHD as our previous 7-day-long treatment. Starting this 2-day-long treatment at day 31/2 or even at day 6, had no, or minimal, effect on its ability to control GVHD. Interestingly, when GCV was started at day 1, no GVL effect was observed. In contrast, when GCV was administered at day 31/2, a significant GVL effect was observed, which was increased if the GCV administration was further delayed to day 6. These data indicate that in this model, the GVL effect is due mainly to donor T cells dividing within the first 6 days following transplantation, and is thus most probably mediated by alloreactive T cells. This is further demonstrated by the inability of remaining donor T cells to control leukemia relapse after a second challenge with P815 cells. It is thus possible that, after the GCV treatment, the immune repertoire contains reduced numbers of alloantigen-specific or leukemic antigen-specific GVL-mediating T cells capable of preventing late leukemia relapse. In this case, it will still be possible to perform delayed donor TK T cell infusion to mediate a GVL effect while controlling GVHD, as already evaluated in a clinical trial.32 The final question we studied in this work was whether the TK/GCV strategy should be associated with the standard prophylactic treatment of GVHD based on CsA. Indeed, there is theoretically a putative antagonism between the cytostatic effect exerted by CsA24,25 and the cell division-dependent destruction of alloreactive T cells mediated by the TK/GCV system. We recently observed that the efficacy of GCV in controlling GVHD was not affected by CsA administration, which could inhibit T-cell division for only 2 days. Thereafter, grafted T cells proliferated despite CsA and could be eliminated by GCV.26 The consequence of CsA administration on GVL when GVHD is controlled by the TK/GCV system remained to be determined. Here, we demonstrate that if CsA is administered during the first 6 days after HSCT before GCV is started, GVL is dramatically reduced. This indicates that the CsA-mediated inhibition of alloreactive T-cell activation during the first 2 days significantly reduced the potency of GVHR and thus GVL. Likewise, CsA administration, although not interfering with GCV-mediated control of GVHD, should preferably be delayed until the end of GCV administration. Our data emphasize that, by a time-optimized scheduling, this therapeutic approach can be tuned to efficiently treat malignant hemopathies. The TK/GCV strategy for the control of GVHD has already been evaluated in clinical trials.33 One study concerned patients who received ex vivo-transduced donor TK T cell infusion for the treatment of relapse or Epstein-Barr virus (EBV)-induced lymphoproliferation occurring after TCD-allogeneic BMT.32 In another study, transduced T cells were administered with a TCD-allogeneic BMT.34 In both cases, GCV was administered to patients after they had developed GVHD. All together, in 6 of 7 patients, GCV administration was associated with complete or partial remission of GVHD. We have previously observed in mice that a course of GCV treatment sufficient to prevent GVHD was not able to completely reverse an advanced GVHD.21 We demonstrate here that an intermediate strategy can be proposed for the treatment of leukemia involving no GCV administration at the time of grafting to improve the GVL effect, followed by a systematic GCV treatment before the occurrence of clinical signs of GVHD. These data obtained in our experimental mouse model should now be translated to the clinical setting of allo-HSCT. Here, GVHR and GVL effects occurred in an MHC mismatch setting. Alloreactivity is therefore robust and probably has a more rapid onset than in HLA-matched situations. Given the variability of major and minor antigen discrepancies encountered in human HLA-matched or HLA-mismatched transplantation, it is presumable that a unique time frame for GCV administration may not apply to all donor-recipient pairs. Also, in our experiments, we used unmanipulated TK T cells from transgenic mice that presumably retain better immune function than T cells transduced ex vivo with a retroviral vector. All together, we have proved the concept that with the TK/GCV system, a time-controlled GVHR permits one to solve the dilemma of allo-HSCT: retaining GVL while controlling GVHD. The definition of appropriate therapeutic scheme(s) for human allo-HSCT can now be investigated only in clinical trials. We indeed are about to test different therapeutic schemes in HLA-matched or haplo-mismatched human HSCT, for the treatment of leukemia or severe autoimmune diseases.
We acknowledge Guillaume Gavori for technical assistance.
Submitted January 17, 2002; accepted April 16, 2002.
Prepublished online as Blood First Edition Paper, May 17, 2002; DOI 10.1182/blood-2002-01-0161.
Supported in part by Association Française contre les Myopathies, the University Pierre and Marie Curie (Paris V) Fondation de France "Leucémie," and the Contre National de la Recherche Scientifique. E.L. is supported by l'Association pour la Recherche sur le Cancer.
E.L. and S.M. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: David Klatzmann, CNRS/UPMC UMR 7087, Hôpital Pitié- Salpêtrière, 83, bd de l'Hôpital, F-75651 Paris Cedex 13, France; e-mail: david.klatzmann{at}chups.jussieu.fr.
1.
Horowitz MM, Gale RP, Sondel PM, et al.
Graft-versus-leukemia reactions after bone marrow transplantation.
Blood.
1990;75:555-562
2.
Martin PJ, Hansen JA, Buckner CD, et al.
Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts.
Blood.
1985;66:664-672
3.
Atkinson K, Storb R, Prentice RL, et al.
Analysis of late infections in 89 long-term survivors of bone marrow transplantation.
Blood.
1979;53:720-731 4. Witherspoon RP, Kopecky K, Storb RF, et al. Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy. Transplantation. 1982;33:143-149[Medline] [Order article via Infotrieve]. 5. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (second of two parts). N Engl J Med. 1975;292:895-902[Medline] [Order article via Infotrieve]. 6. Blazar BR, Korngold R, Vallera DA. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev. 1997;157:79-109[CrossRef][Medline] [Order article via Infotrieve]. 7. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1994;1:279-287[Medline] [Order article via Infotrieve].
8.
Fyfe JA, Keller PM, Furman PA, Miller RL, Elion GB.
Thymidine kinase from herpes simplex virus phosphorylates the new antiviral coumpound, 9-(2-hydroxyethoxymethyl)guanine.
J Biol Chem.
1978;253:8721-8727
9.
St Clair MH, Lambe CU, Furman PA.
Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information.
Antimicrob Agents Chemother.
1987;31:844-849
10.
Tiberghien P, Reynolds CW, Keller J, et al.
Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation?
Blood.
1994;84:1333-1341
11.
Gallot G, Hallet MM, Gaschet J, et al.
Human HLA-specific T-cell clones with stable expression of a suicide gene: a possible tool to drive and control a graft-versus-host- graft-versus-leukemia reaction?
Blood.
1996;88:1098-1103
12.
Cohen JL, Boyer O, Klatzmann D.
Suicide gene therapy of graft-versus-host disease: immune reconstitution with transplanted mature T cells.
Blood.
2001;98:2071-2076
13.
Cohen JL, Boyer O, Salomon B, et al.
Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes.
Blood.
1997;89:4636-4645 14. Helene M, Lake-Bullock V, Bryson JS, Jennings CD, Kaplan AM. Inhibition of graft-versus-host disease: use of a T cell-controlled suicide gene. J Immunol. 1997;158:5079-5082[Abstract]. 15. Cohen JL, Boyer O, Thomas-Vaslin V, Klatzmann D. Suicide gene-mediated modulation of graft-versus-host disease. Leuk Lymphoma. 1999;34:473-480[Medline] [Order article via Infotrieve]. 16. Cohen JL, Saron MF, Boyer O, et al. Preservation of graft-versus-infection effects after suicide gene therapy for prevention of graft-versus-host disease. Hum Gene Ther. 2000;11:2473-2481[CrossRef][Medline] [Order article via Infotrieve].
17.
Drobyski WR, Morse HC 3rd, Burns WH, Casper JT, Sandford G.
Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene.
Blood.
2001;97:2506-2513 18. Cohen JL, Boyer O, Salomon B, et al. Fertile homozygous transgenic mice expressing a functional truncated herpes simplex thymidine kinase delta TK gene. Transgenic Res. 1998;7:321-330[CrossRef][Medline] [Order article via Infotrieve]. 19. Salmon P, Boyer O, Lores P, Jami J, Klatzmann D. Characterization of an intronless CD4 minigene expressed in mature CD4 and CD8 T cells, but not expressed in immature thymocytes. J Immunol. 1996;156:1873-1879[Abstract]. 20. Blazar BR, Taylor PA, Fitzsimmons WE, Vallera DA. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation. J Immunol. 1994;153:1836-1846[Abstract]. 21. Cohen JL, Lacroix-Desmazes S, Charlotte F, et al. Immunological defects after suicide gene therapy of experimental graft-versus-host disease. Hum Gene Ther. 1999;10:2701-2707[CrossRef][Medline] [Order article via Infotrieve].
22.
Maury S, Salomon B, Klatzmann D, Cohen JL.
Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice.
Blood.
2001;98:3156-3158 23. Storb R, Deeg HJ, Pepe M, et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol. 1989;72:567-572[Medline] [Order article via Infotrieve]. 24. Bunjes D, Hardt C, Rollinghoff M, Wagner H. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol. 1981;11:657-661[Medline] [Order article via Infotrieve]. 25. Hess AD, Tutschka PJ. Effect of cyclosporin A on human lymphocyte responses in vitro, I: CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR. J Immunol. 1980;124:2601-2608[Abstract]. 26. Maury S, Litvinova E, Boyer O, et al. Effect of combined cytostatic cyclosporin A and cytolytic suicide gene therapy on the prevention of experimental graft-versus-host disease. Gene Ther. 2002;9:101-107.
27.
Kolb HJ, Mittermuller J, Clemm C, et al.
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.
Blood.
1990;76:2462-2465
28.
Slavin S, Naparstek E, Nagler A, et al.
Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.
Blood.
1996;87:2195-2204
29.
Collins RH Jr, Shpilberg O, Drobyski WR, et al.
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
J Clin Oncol.
1997;15:433-444
30.
Childs R, Chernoff A, Contentin N, et al.
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
N Engl J Med.
2000;343:750-758 31. Weiss L, Lubin I, Factorowich I, et al. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma: role of cell therapy and recombinant IL-2. J Immunol. 1994;153:2562-2567[Abstract].
32.
Bonini C, Ferrari G, Verzeletti S, et al.
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.
Science.
1997;276:1719-1724 33. Anonymous. Human gene marker/therapy clinical protocols (complete updated listing). Hum Gene Ther. 2001;12:2251-2337[CrossRef][Medline] [Order article via Infotrieve].
34.
Tiberghien P, Ferrand C, Lioure B, et al.
Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft.
Blood.
2001;97:63-72
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  A. Chorny, E. Gonzalez-Rey, A. Fernandez-Martin, D. Ganea, and M. Delgado Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response Blood, May 1, 2006; 107(9): 3787 - 3794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bondanza, V. Valtolina, Z. Magnani, M. Ponzoni, K. Fleischhauer, M. Bonyhadi, C. Traversari, F. Sanvito, S. Toma, M. Radrizzani, et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes Blood, March 1, 2006; 107(5): 1828 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Rettig, J. K. Ritchey, J. L. Prior, J. S. Haug, D. Piwnica-Worms, and J. F. DiPersio Kinetics of In Vivo Elimination of Suicide Gene-Expressing T Cells Affects Engraftment, Graft-versus-Host Disease, and Graft-versus-Leukemia after Allogeneic Bone Marrow Transplantation J. Immunol., September 15, 2004; 173(6): 3620 - 3630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Berger, C. A. Blau, M.-L. Huang, J. D. Iuliucci, D. C. Dalgarno, J. Gaschet, S. Heimfeld, T. Clackson, and S. R. Riddell Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model Blood, February 15, 2004; 103(4): 1261 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zoller Tumor Vaccination after Allogeneic Bone Marrow Cell Reconstitution of the Nonmyeloablatively Conditioned Tumor-Bearing Murine Host J. Immunol., December 15, 2003; 171(12): 6941 - 6953. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
TK line
6 (referred to as TK in this report) mice, expressing the 
2 before BMT to day 10 at a dose of
50 mg/kg/d, as previously described.
Time mice were killed on the
experimental scheme. CFSE intensity of hCD4+ in
CD4+ and CD8+ T cells was analyzed at different
time points after grafting. Each histogram is representative of 2 mice.
The peak of highest intensity on the log scale identifies the parent
generation of infused donor T cells. Peaks with decreased CFSE
intensity represent daughter generations that have undergone cell
division. (B) The number of CD4+ and CD8+ donor
T cells in spleens of grafted animals (n = 2 for each group) was
evaluated at day 31/2 by their expression of the hCD4 marker.
The coefficient of variation of duplicates was less than
10%.
